SMMT
NASDAQ · Biotechnology
Summit Therapeutics Inc
$18.08
+0.93 (+5.42%)
SMMT News2 articles
Summit Therapeutics Shares Dive 23% After HARMONi-3 Update Disappoints
Summit Therapeutics shares plummeted 23% after an interim HARMONi-3 update for ivonescimab failed to show early benefit. The trial remains blinded, with final PFS data due in late 2026.
Nvidia Shares Dip Ahead of Key Earnings Report, CEO Cancels India AI Summit
Nvidia shares declined on Friday, with the AI chip leader set to report quarterly earnings on February 25. CEO Jensen Huang has canceled his scheduled appearance at next week's India AI Impact Summit.